Anemia and its association with clinical outcome in heart failure patients undergoing cardiac resynchronization therapy

Journal of Interventional Cardiac Electrophysiology

Volumn 44, Issue 3, 2015, Pages 297-304

  Venkateswaran, Ramkumar V ^a   Freeman, Carolyn ^b   Chatterjee, Neal ^b   Kandala, Jagdesh ^b   Orencole, Mary ^b   Vegh, Eszter M ^b   Parks, Kimberly A ^b   Cowburn, Peter J ^c   Dec, G William ^a,b   Singh, Jagmeet P ^b   Borgquist, Rasmus ^b,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Anemia; Cardiac resynchronization therapy; Heart failure; Prognostic factors; Risk stratification

Indexed keywords

CREATININE; DIURETIC AGENT; BIOLOGICAL MARKER; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; BLOOD; COMORBIDITY; EPIDEMIOLOGY; INCIDENCE; MASSACHUSETTS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANEMIA; BIOMARKERS; BOSTON; CARDIAC RESYNCHRONIZATION THERAPY; COMORBIDITY; FEMALE; HEART FAILURE; HEMOGLOBINS; HUMANS; INCIDENCE; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84947126129     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-015-0062-9     Document Type: Article

References (21)

1. Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., et al. (2004). Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine, 350(21), 2140–2150.
2. Cleland, J. G., Daubert, J. C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., et al. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine, 352(15), 1539–1549.
3. Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., et al. (2014). Heart disease and stroke statistics—2014 update: a report from the American heart association. Circulation, 129(3), e28–e292.
4. McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Bohm, M., Dickstein, K., et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. European Journal of Heart Failure, 14(8), 803–869.
5. Bilchick, K. C., Kamath, S., DiMarco, J. P., & Stukenborg, G. J. (2010). Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in medicare patients. Circulation, 122(20), 2022–2030.
6. European Society of, C., European Heart Rhythm, A, Brignole, M., Auricchio, A., Baron-Esquivias, G., & Bordachar, P. (2013). 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European society of cardiology (ESC). Developed in collaboration with the European heart rhythm association (EHRA). Europace, 15(8), 1070–1118.
7. Felker, G. M., Adams, K. F., Jr., Gattis, W. A., & O'Connor, C. M. (2004). Anemia as a risk factor and therapeutic target in heart failure. Journal of the American College of Cardiology, 44(5), 959–966.
8. Mitchell, J. E. (2007). Emerging role of anemia in heart failure. American Journal of Cardiology, 99(6B), 15D–20D.
9. Anand, I. S. (2008). Anemia and chronic heart failure implications and treatment options. Journal of the American College of Cardiology, 52(7), 501–511.
10. Komajda, M. (2004). Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. Journal of Cardiac Failure, 10(1 Suppl), S1–4.
11. Tang, Y. D., & Katz, S. D. (2008). The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Failure Reviews, 13(4), 387–392.
12. Anand, I. S., Kuskowski, M. A., Rector, T. S., Florea, V. G., Glazer, R. D., Hester, A., et al. (2005). Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation, 112(8), 1121–1127.
13. Horwich, T. B., Fonarow, G. C., Hamilton, M. A., MacLellan, W. R., & Borenstein, J. (2002). Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. Journal of the American College of Cardiology, 39(11), 1780–1786.
14. O'Meara, E., Clayton, T., McEntegart, M. B., McMurray, J. J., Lang, C. C., Roger, S. D., et al. (2006). Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation, 113(7), 986–994.
15. European Heart Rhythm, A., European Society of, C., Heart Rhythm, S., Heart Failure Society of, A., American Society of, E., American Heart, A, et al. (2012). 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm, 9(9), 1524–1576.
16. Weiss, G., & Goodnough, L. T. (2005). Anemia of chronic disease. New England Journal of Medicine, 352(10), 1011–1023.
17. Anand, I. S. (2010). Pathophysiology of anemia in heart failure. Heart Failure Clinics, 6(3), 279–288.
18. O'Meara, E., Rouleau, J. L., White, M., Roy, K., Blondeau, L., Ducharme, A., et al. (2014). Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes. Circulation. Heart Failure, 7(5), 773–781.
19. Anand, I., McMurray, J. J., Whitmore, J., Warren, M., Pham, A., McCamish, M. A., et al. (2004). Anemia and its relationship to clinical outcome in heart failure. Circulation, 110(2), 149–154.
20. Boerrigter, G., Costello-Boerrigter, L. C., Abraham, W. T., Sutton, M. G., Heublein, D. M., Kruger, K. M., et al. (2008). Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. Journal of Cardiac Failure, 14(7), 539–546.
21. Palazzuoli, A., Ruocco, G., Pellegrini, M., De Gori, C., Del Castillo, G., Giordano, N., et al. (2014). The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Therapeutics and Clinical Risk Management, 10, 641–650.